HCW Biologics (HCWB) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
HCW Biologics is the larger company by market cap ($3.6 million vs $2.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCWB | XRTX |
|---|---|---|
| Share price | $1.60 | $1.41 |
| Market cap | $3.58M | $2.56M |
| 1-day change | +4.58% | -23.78% |
| Forward P/E | — | 1.76 |
| EPS (TTM) | $-19.84 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.57 | $7.05 |
| 52-week low | $1.50 | $1.36 |
| Distance from 52-week high | -94.20% | -80.00% |
| Analyst consensus | buy | — |
| Avg. price target upside | +2900.00% | — |
| Average volume | 376.23K | 376.30K |
| Shares outstanding | 2.24M | 1.82M |
| Employees | 35 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Health Care · Biotechnology: Pharmaceutical Preparations
HCWB vs XRTX FAQ
Which is bigger, HCW Biologics or XORTX Therapeutics?
HCW Biologics (HCWB) is larger, with a market capitalization of $3.58M compared with $2.56M for XORTX Therapeutics (XRTX).
Are HCW Biologics and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.